SEC Comment Letter for INOVIO PHARMACEUTICALS, INC. (INO) (CIK 0001055726) (INO) — Feb 11, 2020
INOVIO PHARMACEUTICALS, INC. (INO) (CIK 0001055726)
Date: Feb. 11, 2020 · CIK: 0001055726 · Accession: 0000000000-20-001261
AI Filing Summary & Sentiment
File numbers found in text: 333-236202
Letter
February 7, 2020 J. Joseph Kim, Ph.D. Chief Executive Officer Inovio Pharmaceuticals, Inc. 660 West Germantown Pike, Suite 110 Plymouth Meeting, PA 19462 Re:Inovio Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed January 31, 2020 File No. 333-236202 Dear Mr. Kim: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Ada D. Sarmento at 202-551-3798 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Brian F. Leaf, Esq.
Show Raw Text
February 7, 2020
J. Joseph Kim, Ph.D.
Chief Executive Officer
Inovio Pharmaceuticals, Inc.
660 West Germantown Pike, Suite 110
Plymouth Meeting, PA 19462
Re:Inovio Pharmaceuticals, Inc.
Registration Statement on Form S-3
Filed January 31, 2020
File No. 333-236202
Dear Mr. Kim:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Ada D. Sarmento at 202-551-3798 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Brian F. Leaf, Esq.